{"nctId":"NCT00925899","briefTitle":"Melatonin for Fatigue and Other Symptoms in Patients With Advanced Cancer","startDateStruct":{"date":"2009-10"},"conditions":["Cancer","Fatigue"],"count":72,"armGroups":[{"label":"Melatonin","type":"EXPERIMENTAL","interventionNames":["Drug: Melatonin"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Melatonin","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Answered \"quite a bit\" or \"very much\" to the question \"were you tired?\" (from EORTC QLQ-C15-PAL)\n* Cancer in a palliative phase\n* Written informed consent\n* Age 18 years or above\n\nExclusion Criteria:\n\n* Not capable of understanding or judging information, or fill out a questionnaire\n* Untreated anemia (Hb \\<= 6,0 mmol/L)\n* Untreated hypocalcaemia\n* Systolic blood pressure \\< 100\n* In treatment with coumadin\n* Receiving unstable doses of methylphenidate, corticosteroids or sleeping medicine the past two weeks\n* TSH \\< 0.50 or \\> 5.50 mcL/mL\n* Pregnant or breast feeding","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Fatigue as Measured by the Physical Fatigue Scale in the The Multidimensional Fatigue Inventory (MFI) (Smets EM, Garssen B, Bonke B, et al., J Psychosom Res 39:315-325, 1995)","description":"Primary outcome: Change from baseline to week one in intervention group minus change from baseline to week one in control group.\n\nBecause it was a cross-over trial this was calculated the following way:\n\nOutcomes for arm 1 (melatonin then placebo) were calculated as the difference in mean change scores between week 1 and week 2 (scores for day 7 to day 1-scores for day 17 to day 10). Outcomes for arm 2 (placebo then melatonin) were calculated as the difference in mean change scores between week 2 and week 1 (scores for day 17 to day 10-scores for day 7 to day 1).\n\nThe physical fatigue scale conists of four item each ranging from one to five. The four item were summed and the scae was converted to 0 to 100, where 100 indicated maximum fatigue.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.1","spread":"15.9"},{"groupId":"OG001","value":"-3.9","spread":"18.1"}]}]}]},{"type":"SECONDARY","title":"Insomnia Measured by the Insomnia Item in the Questionnaire EORTC QLQ-C15-PAL","description":"Primary outcome: Change from baseline to week one in intervention group minus change from baseline to week one in control group.\n\nBecause it was a cross-over trial this was calculated the following way:\n\nOutcomes for arm 1 (melatonin then placebo) were calculated as the difference in mean change scores between week 1 and week 2 (scores for day 7 to day 1-scores for day 17 to day 10). Outcomes for arm 2 (placebo then melatonin) were calculated as the difference in mean change scores between week 2 and week 1 (scores for day 17 to day 10-scores for day 7 to day 1).\n\nInsomnia was converted to a 0 til 100 scale according to the scoring manual for EORTC QLQ C15-PAL where 100 indicated maximum insomnia.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.9","spread":"23.4"},{"groupId":"OG001","value":"-4.6","spread":"30.9"}]}]}]},{"type":"SECONDARY","title":"Emotional Function as Measured by the Questionnaire EORTC QLQ-C15-PAL (Groenvold M, Petersen MA, Aaronson NK, et al, Eur J Cancer 42:55-64, 2006)","description":"Change from baseline to week one in intervention group minus change from baseline to week one in control group.\n\nBecause it was a cross-over trial this was calculated the following way:\n\nOutcomes for arm 1 (melatonin then placebo) were calculated as the difference in mean change scores between week 1 and week 2 (scores for day 7 to day 1-scores for day 17 to day 10). Outcomes for arm 2 (placebo then melatonin) were calculated as the difference in mean change scores between week 2 and week 1 (scores for day 17 to day 10-scores for day 7 to day 1).\n\nEmotional function was converted to a 0 til 100 scale according to the scoring manual for EORTC QLQ C15-PAL where 100 indicated the best possible emotional function.\n\nNote outcome reported for complete compliers","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"23.5"},{"groupId":"OG001","value":"3.3","spread":"18.5"}]}]}]},{"type":"SECONDARY","title":"Pain as Measured by the Questionnaire EORTC QLQ-C15-PAL (Groenvold M, Petersen MA, Aaronson NK, et al, Eur J Cancer 42:55-64, 2006)","description":"Change from baseline to week one in intervention group minus change from baseline to week one in control group.\n\nBecause it was a cross-over trial this was calculated the following way:\n\nOutcomes for arm 1 (melatonin then placebo) were calculated as the difference in mean change scores between week 1 and week 2 (scores for day 7 to day 1-scores for day 17 to day 10). Outcomes for arm 2 (placebo then melatonin) were calculated as the difference in mean change scores between week 2 and week 1 (scores for day 17 to day 10-scores for day 7 to day 1).\n\nPain was converted to a 0 til 100 scale according to the scoring manual for EORTC QLQ C15-PAL where 100 indicated maximum pain.\n\nNote outcome reported for complete compliers","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"19.3"},{"groupId":"OG001","value":"1.9","spread":"22.2"}]}]}]},{"type":"SECONDARY","title":"Quality of Life as Measured by the Questionnaire EORTC QLQ-C15-PAL (Groenvold M, Petersen MA, Aaronson NK, et al, Eur J Cancer 42:55-64, 2006)","description":"Change from baseline to week one in intervention group minus change from baseline to week one in control group.\n\nBecause it was a cross-over trial this was calculated the following way:\n\nOutcomes for arm 1 (melatonin then placebo) were calculated as the difference in mean change scores between week 1 and week 2 (scores for day 7 to day 1-scores for day 17 to day 10). Outcomes for arm 2 (placebo then melatonin) were calculated as the difference in mean change scores between week 2 and week 1 (scores for day 17 to day 10-scores for day 7 to day 1).\n\nQuality of Life was converted to a 0 til 100 scale according to the scoring manual for EORTC QLQ C15-PAL where 100 indicated best possible quality of life.\n\nNote outcome reported for complete compliers","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"13.6"},{"groupId":"OG001","value":"-3.2","spread":"19.2"}]}]}]},{"type":"SECONDARY","title":"Appetite Loss as Measured by the Questionnaire EORTC QLQ-C15-PAL (Groenvold M, Petersen MA, Aaronson NK, et al, Eur J Cancer 42:55-64, 2006)","description":"Change from baseline to week one in intervention group minus change from baseline to week one in control group.\n\nBecause it was a cross-over trial this was calculated the following way:\n\nOutcomes for arm 1 (melatonin then placebo) were calculated as the difference in mean change scores between week 1 and week 2 (scores for day 7 to day 1-scores for day 17 to day 10). Outcomes for arm 2 (placebo then melatonin) were calculated as the difference in mean change scores between week 2 and week 1 (scores for day 17 to day 10-scores for day 7 to day 1).\n\nAppetite loss was converted to a 0 til 100 scale according to the scoring manual for EORTC QLQ C15-PAL where 100 indicated maximum appetite loss (worst possible).\n\nNote outcome reported for complete compliers","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"25.4"},{"groupId":"OG001","value":"-3.2","spread":"21.6"}]}]}]},{"type":"SECONDARY","title":"General Fatigue Measured by the The Multidimensional Fatigue Inventory (MFI)","description":"Change from baseline to week one in intervention group minus change from baseline to week one in control group.\n\nBecause it was a cross-over trial this was calculated the following way:\n\nOutcomes for arm 1 (melatonin then placebo) were calculated as the difference in mean change scores between week 1 and week 2 (scores for day 7 to day 1-scores for day 17 to day 10). Outcomes for arm 2 (placebo then melatonin) were calculated as the difference in mean change scores between week 2 and week 1 (scores for day 17 to day 10-scores for day 7 to day 1).\n\nThe general fatigue scale that consits of four items was converted to a 0 til 100 scale where 100 indicated maximum (worst possible) fatigue.\n\nNote outcome reported for complete compliers","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.2","spread":"18.6"},{"groupId":"OG001","value":"-2.1","spread":"24.8"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":34},"commonTop":[]}}}